Physician profile
Frederick Min
NPI 1366682429
$13,321.82
in general payments reported to CMS, 2019-2025
75 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $1,236 · 2021: $766 · 2022: $1,616 · 2023: $4,282 · 2024: $2,664 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,964 · Consulting Fee: $2,280 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,964.14 |
| Consulting Fee | $2,280.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,415.61 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $1,107.84 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Novartis Pharmaceuticals Corporation | $782.22 | 2019-2025 | |
| Janssen Biotech, INC. | $702.36 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $496.71 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $454.16 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $450.02 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $350.04 | 2020-2025 | Enhertu, Calquence, Lynparza |
| Pfizer INC. | $308.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $289.88 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $288.11 | 2021-2025 | |
| Amgen INC. | $273.95 | 2021-2023 | Evenity, Lumakras, Kyprolis |
| Seagen INC. | $244.28 | 2021-2023 | Tivdak, Tukysa, Adcetris |
| Genzyme Corporation | $235.55 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.42 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $201.89 | 2022-2025 | Fotivda |
| Abbvie INC. | $200.19 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $193.65 | 2020-2025 | Onivyde, Tazverik, Somatuline Depot |
| Lilly USA, LLC | $179.30 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $177.58 | 2023-2024 | Krazati |
| Genentech USA, INC. | $174.33 | 2022-2025 | Venclexta, Tecentriq, Columvi |
| Genmab U.S., INC. | $171.33 | 2023-2025 | Epkinly |
| Celgene Corporation | $168.17 | 2020-2023 | Pomalyst |
| Pharmaessentia USA Corporation | $167.22 | 2022-2025 | Besremi |
| Gilead Sciences, INC. | $150.32 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $143.13 | 2023-2024 | Libtayo |
| Sobi, INC | $138.22 | 2022-2025 | |
| Dexcom, INC. | $134.07 | 2024 | Dexcom G7 Gss (161) |
| Janssen Pharmaceuticals, INC | $131.87 | 2019-2025 | Erleada |
| Array Biopharma INC | $117.29 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $113.95 | 2021-2023 | Imbruvica |
| Beigene USA, INC. | $110.62 | 2022-2024 | Brukinsa |
| Puma Biotechnology, INC. | $107.04 | 2021-2025 | |
| Adc Therapeutics America, INC. | $105.37 | 2022-2025 | |
| Exelixis INC. | $103.48 | 2023-2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $93.66 | 2024-2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $90.86 | 2022-2025 | Clonoseq |
| Boston Scientific Corporation | $87.42 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Emd Serono, INC. | $86.21 | 2021-2025 | |
| Tersera Therapeutics LLC | $85.34 | 2023-2025 | Zoladex, Xermelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.16 | 2021-2022 | |
| Beone Medicines USA, INC. | $74.72 | 2025 | Brukinsa |
| Tactile Systems Technology INC | $74.56 | 2021-2025 | Flexitouch Plus, Nimbl |
| Global Blood Therapeutics, INC. | $74.32 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $67.02 | 2019-2022 | |
| Kyowa Kirin, INC. | $66.20 | 2023-2024 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $61.73 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $58.81 | 2023-2025 | Orserdu |
| Astellas Pharma US INC | $50.51 | 2021-2025 | Cresemba |
| Fresenius Kabi USA, LLC | $50.07 | 2024-2025 | Stimufend |
| Pharmacosmos Therapeutics INC. | $49.67 | 2024-2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $49.11 | 2021-2025 | Qinlock, Tgct |
| Morphosys, US INC. | $44.60 | 2022-2023 | Monjuvi |
| Taiho Oncology, INC. | $43.21 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.33 | 2023 | Opdivo, Eliquis |
| Legend Biotech USA INC. | $32.59 | 2025 | Carvykti |
| Sumitomo Pharma America, INC. | $31.94 | 2024 | Orgovyx |
| Menarini Silicon Biosystems, INC. | $31.85 | 2025 | |
| Blueprint Medicines Corporation | $31.20 | 2025 | Ayvakit |
| Tesaro, INC. | $29.07 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.94 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.41 | 2023-2024 | Givlaari |
| Immunogen, INC. | $25.15 | 2023 | Elahere |
| G1 Therapeutics, INC. | $24.22 | 2023 | Cosela |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Springworks Therapeutics, INC. | $23.24 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $21.61 | 2022 | |
| Shield Therapeutics INC | $20.16 | 2024 | |
| Spectrum Pharmaceuticals INC. | $19.10 | 2023 | Rolvedon |
| Shire North American Group INC | $17.14 | 2019 | |
| Recordati_rare_diseases_inc. | $15.74 | 2023 | Sylvant |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.